Worth reading
36Immaterial
Scored from 5 of 6 sectionsDirection
Deterioration
Direction inferred from the company’s description.Scale
-39.7
Year-on-year change in operating profit (%)Wording
Conditional
How definitive the wording is.Results for this period
First quarter2025年6月1日〜2025年8月31日ConsolidatedJapanese GAAPNet Sales435¥ millionYear on year -1.3%Progress 25.5%
Operating profit53¥ millionYear on year -39.7%Progress 26.5%
Ordinary income81¥ millionYear on year -5.5%Progress 35.4%
Net income attributable to owners of the parent56¥ millionYear on year -6.3%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share24.94円
Financial position at period-end
Total assets9,990¥ million
of which net assets 2,132 ¥ millionEquity ratio 21.3%vs. prior year-end -1.5pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥1,703 million (YoY +13.3%)
Operating profit¥200 million (YoY -33.2%)
Ordinary income¥229 million (YoY -23.7%)
Profit attributable to owners of the parent¥151 million (YoY -31.6%)
Annual Dividend Forecast¥20 → ¥20（0.0%）
Factors Behind Changes in Business Performance
Ｆ＆Ｉは取組案件の見直し完了により売上高が1.7％増加。Ｃ＆Ｂｒは前年同期の大型医療機器等の大きな物販売上の反動で売上高が24.4％減少。ＨＲ＆ＯＳは外国人材・経営人材・経理労務管理業務人材の紹介への注力と調剤薬局業務アウトソーシングサービスの増収寄与により売上高が64.3％増加。
Disclosure regarding the going concern assumption
No applicable matters
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidation新規：0社、除外：0社（該当会社なし）
Depreciation and amortization¥3,543 thousand
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingNone (対象者：Not applicable)
Issued Shares at Period-End2,268,000株
Treasury Shares at Period-End— shares
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2025年6月1日〜2025年8月31日 |
| Net Sales | ¥435 million (YoY -1.3%) |
| Operating profit | ¥53 million (YoY -39.7%) |
| Ordinary income | ¥81 million (YoY -5.5%) |
| Profit attributable to owners of the parent | ¥56 million (YoY -6.3%) |
| Net income per share | 24.94円 |
| Equity ratio | End of the current fiscal period 21.3 / End of previous period 22.8 |
| Total assets | ¥9,990 million |
| Net assets | ¥2,132 million |
| Full-year earnings forecast | Net Sales ¥1,703 million (YoY +13.3%) / Operating profit ¥200 million (YoY -33.2%) / Ordinary income ¥229 million (YoY -23.7%) / Profit attributable to owners of the parent ¥151 million (YoY -31.6%) |
| Annual Dividend Forecast | ¥20 → ¥20（0.0%） |
| Depreciation and amortization | ¥3,543 thousand |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | 新規：0社、除外：0社（該当会社なし） |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | None (対象者：Not applicable) |
| Issued Shares at Period-End | 2,268,000株 |
| Treasury Shares at Period-End | — shares |
| Factors Behind Changes in Business Performance | Ｆ＆Ｉは取組案件の見直し完了により売上高が1.7％増加。Ｃ＆Ｂｒは前年同期の大型医療機器等の大きな物販売上の反動で売上高が24.4％減少。ＨＲ＆ＯＳは外国人材・経営人材・経理労務管理業務人材の紹介への注力と調剤薬局業務アウトソーシングサービスの増収寄与により売上高が64.3％増加。 |
Items this document does not state (15)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodRevision to Earnings ForecastPayout ratioShareholder Return PolicySegment revenueSegment profitRegional salesOrders received and order backlogImpairment lossBreakdown of extraordinary income (loss)Material subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Ｃ＆Ｂｒサービスは前年同期に大型医療機器等の大きな物販売上があった反動で減収となった。ＨＲ＆ＯＳサービスは外国人材や経営人材等の紹介への注力に加え、調剤薬局業務のアウトソーシングサービスが増収に寄与した。Ｆ＆Ｉサービスはファクタリングにおける取組案件の見直しが前期で概ね完了した。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.